- Home
- ZEO vs RLYB Comparison
ZEO vs RLYB Comparison
Compare ZEO & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- RLYB
- Stock Information
- Founded
- ZEO 2005
- RLYB 2018
- Country
- ZEO United States
- RLYB United States
- Employees
- ZEO N/A
- RLYB N/A
- Industry
- ZEO
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- RLYB Health Care
- Exchange
- ZEO NYSE
- RLYB Nasdaq
- Market Cap
- ZEO 23.0M
- RLYB 27.2M
- IPO Year
- ZEO N/A
- RLYB 2021
- Fundamental
- Price
- ZEO $1.49
- RLYB $0.60
- Analyst Decision
- ZEO
- RLYB Buy
- Analyst Count
- ZEO 0
- RLYB 5
- Target Price
- ZEO N/A
- RLYB $9.75
- AVG Volume (30 Days)
- ZEO 12.8K
- RLYB 43.4K
- Earning Date
- ZEO 05-14-2025
- RLYB 05-08-2025
- Dividend Yield
- ZEO N/A
- RLYB N/A
- EPS Growth
- ZEO N/A
- RLYB N/A
- EPS
- ZEO N/A
- RLYB N/A
- Revenue
- ZEO $77,582,314.00
- RLYB $636,000.00
- Revenue This Year
- ZEO N/A
- RLYB N/A
- Revenue Next Year
- ZEO N/A
- RLYB N/A
- P/E Ratio
- ZEO N/A
- RLYB N/A
- Revenue Growth
- ZEO N/A
- RLYB N/A
- 52 Week Low
- ZEO $1.05
- RLYB $0.60
- 52 Week High
- ZEO $5.87
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- ZEO 32.69
- RLYB 45.01
- Support Level
- ZEO $1.50
- RLYB $0.63
- Resistance Level
- ZEO $1.79
- RLYB $0.73
- Average True Range (ATR)
- ZEO 0.10
- RLYB 0.08
- MACD
- ZEO 0.01
- RLYB 0.00
- Stochastic Oscillator
- ZEO 3.12
- RLYB 27.40
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.